Stay updated on Nivolumab Plus Bevacizumab in GBM Clinical Trial
Sign up to get notified when there's something new on the Nivolumab Plus Bevacizumab in GBM Clinical Trial page.

Latest updates to the Nivolumab Plus Bevacizumab in GBM Clinical Trial page
- Check3 days agoChange DetectedA unified 'Locations' section now lists Massachusetts and Ohio, replacing the prior separate 'Massachusetts Locations' and 'Ohio Locations' entries. The footer link to 'HHS Vulnerability Disclosure' has been removed and the page revision updated from v3.3.2 to v3.3.3.SummaryDifference0.3%

- Check10 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check32 days agoChange DetectedPublications are now described as automatically filled from PubMed and may not be about the study. The page revision is updated to v3.3.2.SummaryDifference0.1%

- Check39 days agoChange DetectedRemoved the general government funding status notice from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check53 days agoChange DetectedThe page shows minor updates to Study Record Dates and timestamps, with no changes to core trial design, eligibility criteria, endpoints, or locations. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check82 days agoChange DetectedMajor updates: a government funding status notice and a new version tag (v3.2.0) replace the old version (v3.0.2), signaling updated operating status and software/version information.SummaryDifference2%

- Check103 days agoChange DetectedRevision updated from v3.0.1 to v3.0.2; the 'Back to Top' element was removed.SummaryDifference0.1%

Stay in the know with updates to Nivolumab Plus Bevacizumab in GBM Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab Plus Bevacizumab in GBM Clinical Trial page.